Corvus Pharmaceuticals, Inc. Annual Report: A Look Back and What's Ahead

Corvus Pharmaceuticals (NASDAQ: CRVS) has released its latest annual report for the fiscal year ended December 31, 2025, offering investors a comprehensive look at its strategic direction, financial health, and the progress of its innovative drug pipeline. As a "smaller reporting company" and "non-accelerated filer," Corvus follows fewer financial reporting requirements than larger firms, reflecting its current size, but maintains a strong commitment to transparency. This report details the company's key initiatives and future plans.

Business Overview

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing new oncology and immunology therapies. Its strategy focuses on advancing a pipeline of drug candidates through clinical trials, primarily addressing significant unmet medical needs in cancer and autoimmune diseases. As of March 12, 2026, the company had approximately 83.99 million shares of common stock outstanding. The public float – shares available for public trading – was valued at roughly $251.9 million as of June 30, 2025.

Key Pipeline Developments & Clinical Progress

The company's future success hinges on its lead product candidates:

• Soquelitinib (formerly CPI-818): This oral ITK inhibitor is a central focus. In 2025, Corvus successfully completed enrollment for its Phase 2 clinical trial in patients with T-cell lymphomas. Initial data from this trial, expected in mid-2026, will be a significant milestone. The company also initiated a Phase 1 study in late 2025 to explore soquelitinib's potential in other autoimmune conditions.
• Ciforadenant: An adenosine A2A receptor antagonist, ciforadenant is currently being evaluated in combination therapies for various solid tumors. Following promising preclinical data in specific tumor types, Corvus is engaged in ongoing collaboration discussions for its further development.
• Mupadolimab: This anti-CD73 antibody is in early-stage clinical development for oncology. Corvus advanced patient recruitment for its Phase 1b trial, which combines mupadolimab with other immunotherapies. The company expects preliminary safety data by year-end 2026.

Beyond these lead assets, Corvus continues to invest in preclinical research. It plans to advance at least one new candidate into IND-enabling studies in 2026, targeting novel immune pathways. (IND-enabling studies are the necessary preclinical tests and data collection required before a drug can begin human clinical trials.)

Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)

Overview of Operations: As a clinical-stage biopharmaceutical company, Corvus Pharmaceuticals' operations focus primarily on research and development activities. The company has not yet generated revenue from product sales. It anticipates incurring significant expenses for the foreseeable future as it continues to advance its product candidates through clinical development and seeks regulatory approvals.

Financial Performance (Fiscal Year 2025): For the fiscal year ended December 31, 2025, Corvus reported:

• Revenue: Totaling approximately $5.5 million, revenue came primarily from research grants and collaboration agreements, a slight increase from the prior year. This reflects the company's clinical-stage status, as it generated no product sales revenue.
• Net Loss: The company reported a net loss of approximately $68.2 million, or $0.81 per share. This compares to a net loss of $62.0 million in 2024. This increase was primarily due to higher research and development (R&D) expenses, which rose to $58.0 million as clinical trials for soquelitinib and mupadolimab progressed. General and administrative expenses remained relatively stable at $15.7 million.
• Other Income: Other income, mainly from interest earned on cash and marketable securities, was modest. This reflects the current interest rate environment and the company's cash management strategy.

Financial Health (Liquidity and Capital Resources):

• Cash Position: As of December 31, 2025, Corvus held $75.3 million in cash, cash equivalents, and marketable securities. Based on current operational plans and projected R&D spending, this provides an estimated cash runway into the third quarter of 2027.
• Funding: The company raised approximately $30 million through an at-the-market (ATM) equity offering during 2025. (An ATM offering allows a company to sell shares directly into the market over time.) This funding supports its clinical programs and general corporate purposes. Future funding will likely involve additional equity offerings, strategic partnerships, or non-dilutive financing.
• Cash Flows: In 2025, the company primarily used cash for operating activities, driven by increased R&D expenditures. Cash from financing activities mainly came from the ATM equity offering. Investing activities were minimal, primarily related to purchases and sales of marketable securities.
• Debt: As of December 31, 2025, Corvus Pharmaceuticals had no significant long-term debt obligations. The company's financing strategy has historically relied on equity offerings and strategic collaborations.
• Off-Balance Sheet Arrangements: The company has no off-balance sheet arrangements – financial commitments not listed on the main balance sheet – that currently affect or could reasonably affect its financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.
• Contractual Obligations: The company's primary contractual obligations relate to operating leases for its facilities and commitments under its clinical trial and manufacturing agreements. These obligations align with its operational scale.

Critical Accounting Policies and Estimates: Management's discussion and analysis of financial condition and results of operations rely on the company's consolidated financial statements. These statements are prepared in accordance with U.S. generally accepted accounting principles (GAAP), the standard accounting practices in the U.S. Preparing these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, as well as the disclosure of contingent assets and liabilities. Key accounting policies include those related to research and development expenses, stock-based compensation, and revenue recognition.

Competitive Position

The biopharmaceutical industry is highly competitive and features rapid technological advances. Corvus Pharmaceuticals competes with numerous pharmaceutical, biotechnology, and specialty pharmaceutical companies. Many of these competitors possess substantially greater financial, technical, and human resources than Corvus. Key competitive factors include the efficacy, safety, and tolerability profiles of product candidates, the timing of market entry, intellectual property protection, and the availability of adequate manufacturing and commercialization capabilities.

Corvus aims to differentiate its product candidates through novel mechanisms of action and by targeting specific patient populations or disease indications with high unmet medical needs. For example, soquelitinib's focus as an ITK inhibitor for T-cell lymphomas and autoimmune diseases represents a targeted approach. The company's intellectual property portfolio, including patents and patent applications covering its drug candidates and their uses, is crucial for maintaining a competitive edge. However, the competitive landscape for oncology and immunology therapies is dynamic, with new therapies and treatment paradigms constantly emerging. Corvus's ability to successfully develop, obtain regulatory approval for, and commercialize its product candidates will depend on its ability to compete effectively in this challenging environment.

Key Risks and Challenges

Investing in Corvus Pharmaceuticals carries significant risks inherent to the biotechnology sector:

• Clinical Trial Success: Drug candidates may fail to demonstrate efficacy or safety in ongoing or future clinical trials, or may not receive regulatory approval.
• Regulatory Approval: Obtaining FDA and international regulatory approvals is a lengthy, complex, and uncertain process.
• Funding: Corvus is a development-stage company and will require substantial additional funding to complete clinical trials and commercialize any approved products. There is no guarantee that Corvus can secure such funding on favorable terms or at all.
• Competition: The oncology and immunology markets are highly competitive, with numerous large pharmaceutical companies and smaller biotechs developing similar therapies.
• Intellectual Property: The company's success depends on its ability to protect its intellectual property and operate without infringing on the rights of others.

Future Outlook for 2026 and Beyond

Corvus Pharmaceuticals remains focused on executing its clinical development strategy. Key milestones for 2026 include:

• Reporting initial Phase 2 data for soquelitinib in T-cell lymphomas.
• Advancing the Phase 1 study of soquelitinib in autoimmune indications.
• Providing updates on the Phase 1b trial for mupadolimab.
• Initiating IND-enabling studies for a new preclinical candidate.

The company's ability to achieve these milestones and secure additional funding will be critical to its long-term success. Investors should closely monitor clinical trial results, regulatory interactions, and the company's cash burn rate as it navigates the high-risk, high-reward landscape of drug development.